All news

Pic:getty/courtneyk

Merck picks up another ADC agreement

By Ben Hargreaves

With speculation that Merck is lining up a multi-billion dollar acquisition in the ADC space, the company has agreed a second collaboration deal with Sichuan Kelun Pharmaceutical.

Pic:getty/andrewpopov

GSK ups sales guidance on back of Shingrix strength

By Ben Hargreaves

GSK’s first quarter following the demerger of its consumer health business sees the company raise its 2022 sales guidance to between 6-8%, up from 5-7% on its previous estimation.

© GettyImages/aquaArts studio

Alnylam has obesity gene target in its sights

By Jane Byrne

Cambridge, Massachusetts based, Alnylam Pharmaceuticals, along with collaborators, has identified mutations in the INHBE gene linked with protection against abdominal obesity.

Pic:getty/monkeybusinessimages

New investment in monkeypox vaccine assessment tools

By Rachel Arthur

The Coalition for Epidemic Preparedness Innovations (CEPI) will provide funding of up to $375,000 to the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the UK Health Security Agency (UKHSA) to support the development of laboratory tools...

© GettyImages/ardaguldogan

FDA reviewing higher dose Hyrimoz biosimilar

By Jane Byrne

The US FDA has accepted a supplemental biologics license application (sBLA) from Sandoz for a high concentration formulation of 100 mg/mL (HCF) of its biosimilar, Hyrimoz.

Pic:getty/markrubens

WuXi Biologics to build CRDMO center in Singapore

By Rachel Arthur

CDMO WuXi Biologics will invest $1.4bn in a 10 year investment plan to expand its research, development, and large-scale drug substance and drug product manufacturing capacity and capabilities in Singapore.